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AbstrAct
Objectives To systematically review the quality of 
reporting of pilot and feasibility of cluster randomised trials 
(CRTs). In particular, to assess (1) the number of pilot CRTs 
conducted between 1 January 2011 and 31 December 
2014, (2) whether objectives and methods are appropriate 
and (3) reporting quality.
Methods We searched PubMed (2011–2014) for CRTs 
with ‘pilot’ or ‘feasibility’ in the title or abstract; that 
were assessing some element of feasibility and showing 
evidence the study was in preparation for a main 
effectiveness/efficacy trial. Quality assessment criteria 
were based on the Consolidated Standards of Reporting 
Trials (CONSORT) extensions for pilot trials and CRTs.
results Eighteen pilot CRTs were identified. Forty-four 
per cent did not have feasibility as their primary objective, 
and many (50%) performed formal hypothesis testing 
for effectiveness/efficacy despite being underpowered. 
Most (83%) included ‘pilot’ or ‘feasibility’ in the title, and 
discussed implications for progression from the pilot to the 
future definitive trial (89%), but fewer reported reasons 
for the randomised pilot trial (39%), sample size rationale 
(44%) or progression criteria (17%). Most defined the 
cluster (100%), and number of clusters randomised (94%), 
but few reported how the cluster design affected sample 
size (17%), whether consent was sought from clusters 
(11%), or who enrolled clusters (17%).
conclusions That only 18 pilot CRTs were identified 
necessitates increased awareness of the importance 
of conducting and publishing pilot CRTs and improved 
reporting. Pilot CRTs should primarily be assessing 
feasibility, avoiding formal hypothesis testing for 
effectiveness/efficacy and reporting reasons for the pilot, 
sample size rationale and progression criteria, as well 
as enrolment of clusters, and how the cluster design 
affects design aspects. We recommend adherence to the 
CONSORT extensions for pilot trials and CRTs.
bAckgrOund
In a cluster randomised trial (CRT) clus-
ters, rather than individuals, are the units of 
randomisation. A cluster is a group (usually 
predefined) of one or more individuals. For 
example, clusters could be hospitals and the 
individuals, the patients within those hospi-
tals. CRTs are often chosen for logistical 
reasons, prevention of contamination across 
individuals or because the intervention 
is targeted at the cluster level. CRTs are 
useful for evaluating complex interventions. 
However, they have added complexity in 
terms of design, implementation and analysis 
and so it is important to ensure that carrying 
out a CRT is feasible before conducting the 
future definitive trial.1
A feasibility study conducted in advance 
of a future definitive trial is a study designed 
to answer the question about whether the 
study can be done and whether one should 
proceed with it. A pilot study answers the 
same question but in such a study part or all 
of the future trial is carried out on a smaller 
scale.2 Thus, all pilot studies are also feasibility 
studies. Pilot studies can be randomised or 
non-randomised; for brevity we use the term 
pilot CRT throughout this paper to refer to 
a randomised study with a clustered design 
that is in preparation for a future definitive 
trial assessing effectiveness/efficacy.3 4 The 
focus of pilot trials is on investigating areas of 
uncertainty about the future definitive trial to 
see whether it is feasible to carry out, so the 
data, methods and analysis are different from 
an effectiveness/efficacy trial. In particular, 
more data might be collected on items such 
as recruitment and retention to assess feasi-
bility, methods may include specifying criteria 
to judge whether to proceed with the future 
definitive trial, and analysis is likely to be 
based on descriptive statistics since the study 
is not powered for formal hypothesis testing 
for effectiveness/efficacy.
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Research
strengths and limitations of this study
 ► We used a robust search and data extraction 
procedure, including validation of the screening/
sifting process and double data extraction.
 ► We may have missed some studies, since our 
criteria excluded studies not including ‘pilot’ or 
‘feasibility’ in the title or abstract, and those not 
clearly in preparation for a main trial. 
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Arnold et al highlight the importance of pilot studies 
being of high quality.5 Good reporting quality is essential to 
show how the pilot has informed the future definitive trial 
as well as to allow readers to use the results in preparing 
for similar future trials. The number of pilot and feasibility 
studies in the literature is increasing. However, Arain et al 
indicate that reporting of pilot studies is poor.6 There are 
no previous reviews of the reporting quality of pilot CRTs, 
despite the extra complications arising from the clustered 
structure. The aim of this review is to reveal the quality 
of reporting of pilot CRTs published between 1 January 
2011 and 31 December 2014. We extracted information 
to describe the sample of pilot CRTS and to assess quality, 
with quality criteria based on the Consolidated Standards 
of Reporting Trials (CONSORT) extension for CRTs,7 
and a CONSORT extension for pilot trials for which SE 
and CC were involved in the final stages of development 
during this review.3 4 We present recommendations for 
improving the conduct, analysis and reporting of these 
studies and expect this to improve the quality, usefulness 
and interpretation of pilot CRTs in the future. We know 
current reporting of CRTs is suboptimal,8–11 and thus we 
expected the reporting of pilot CRTs to be even poorer.
The questions addressed by this review are:
1. How many pilot CRTs have been conducted between 
1 January 2011 and 31 December 2014?
2. Are pilot CRTs using appropriate objectives and meth-
ods?
3. To what extent is the quality of reporting of pilot CRTs 
sufficient?
MethOds
Inclusion and exclusion criteria
We included papers published in English with a publica-
tion date (print or electronic) between 1 January 2011 
and 31 December 2014. We chose the start date to be 
after the updated CONSORT 2010 was published.12 We 
estimated a search covering 4 years would give us a reason-
able number of papers to perform our quality assessment, 
and that later papers would be similar in terms of quality 
of reporting since the CONSORT for pilot trials was not 
published until the end of 2016. The study had to be a 
CRT, have the word ‘pilot’ or ‘feasibility’ in the title or 
abstract, be assessing some element of feasibility and show 
evidence that the study was in preparation for a specific 
trial assessing effectiveness/efficacy that is planned to go 
ahead if the pilot trial suggests it is feasible (ie, not just a 
general assessment of feasibility issues to help researchers 
in general, although pilot trials may do this as an addi-
tion). Regardless of how authors described a study, we 
did not consider it to be a pilot trial if it was only looking 
at effectiveness/efficacy because we wanted to exclude 
those studies that claim to be a pilot/feasibility trial 
simply as justification for small sample size.13 The paper 
had to be reporting results (ie, not a protocol or statis-
tical analysis plan) and had to be the first published paper 
reporting pilot outcomes (ie, not an extension/follow-up 
study for a pilot study already reported, and not a second 
paper reporting further pilot outcomes). Interim anal-
yses, analyses before the study was complete and internal 
pilots were excluded; the CONSORT extension for pilot 
trials on which we based the quality assessment does not 
apply to internal pilots.3 4 No studies were excluded on 
the basis of quality since the aim was to assess the quality 
of reporting.
data sources and search methods
We searched PubMed for relevant papers in September 
2015. We searched for the words ‘pilot’ or ‘feasibility’ 
in the title or abstract, a search strategy similar to that 
used by Lancaster et al.14 We combined this with a search 
strategy to identify CRTs; this was similar to the strategy 
used by Diaz-Ordaz et al.8 The full electronic search 
strategy is given in online supplementary appendix 1.
sifting and validation
The titles and abstracts of all papers identified by the elec-
tronic search were screened by CC for possible inclusion. 
Full texts were obtained for those papers identified as 
definitely or possibly satisfying the inclusion criteria and 
sifted by CC for inclusion. As validation, CL carried out 
the same screening and sifting process independently on 
a 10% random sample of electronically identified papers. 
For full texts where there was uncertainty whether the 
paper should be included, it was referred to SE for a final 
decision.
refining the inclusion process
We refined the screening and sifting process following 
piloting. In particular, we rejected a more restrictive 
PubMed search that required ‘pilot’ or ‘feasibility’ in the 
title rather than allowing these words to occur in the title 
or abstract because this missed relevant papers; we altered 
the order of the exclusion criteria to make the process 
more streamline; and we relaxed one inclusion criteria, 
requiring evidence that the pilot trial was in prepara-
tion for a future definitive trial rather than an explicit 
statement that authors were planning a future definitive 
trial. The protocol was updated, and is available from the 
corresponding author.
data extraction
CC and CL independently extracted data from all papers 
selected for inclusion in the review, and followed rules 
on what to extract (see 'Further information' column of 
online supplementary appendix 2). Extracted data were 
recorded in an Excel spreadsheet. Discrepancies were 
resolved by discussion between CC and CL, and where 
agreement could not be reached a final decision was 
made by SE.
For each pilot CRT included in the review, we extracted 
information to describe the trials, including publication 
date (print date unless there was an earlier electronic 
date), country in which the trial was set, number of 
clusters randomised, method of cluster randomisation 
and following the CONSORT extension for pilot trials’ 
group.bmj.com on January 13, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
 3Chan CL, et al. BMJ Open 2017;7:e016970. doi:10.1136/bmjopen-2017-016970
Open Access
recommendation to focus on objectives rather than 
outcomes, the primary objective. We defined the primary 
objective using method similar to that used by Diaz-Ordaz 
et al8 for primary outcomes that is, as that specified by the 
author, else the objective used in the sample size justifica-
tion, or else the first objective mentioned in the abstract 
or else main text.
To assess whether the pilot trials were using appropriate 
objectives and methods, we collected information on 
whether the primary objective was about feasibility, the 
method used to address the main feasibility objective, the 
rationale for numbers in the pilot trial and whether there 
was formal hypothesis testing for, or statements about, 
effectiveness/efficacy without a caveat about the small 
sample size.
To assess reporting quality, we created a list of quality 
assessment items based on the CONSORT extension for 
pilot trials.3 4 We also looked at the CONSORT extension 
for CRTs,7 and incorporated any cluster-specific items 
into our quality assessment items. Where a CRT item 
became less relevant in the context of a pilot trial, we 
did not extract it (eg, whether variation in cluster sizes 
was formally considered in the sample size calculation). 
In addition, where there was a substantial difference 
between the item for the CONSORT extension for CRTs 
and that for the pilot trial extension and the items were 
not compatible, we used the latter item (eg, focusing on 
objectives rather than outcomes). We recognised the 
need to balance comprehensiveness and feasibility.11 
Therefore, where items referred to objectives or methods, 
we extracted this for the primary objective only. We also 
did not extract on whether papers reported a structured 
summary of trial design, methods, results and conclu-
sions. The final version of the full list of data extracted, 
and further information on each item extracted, is 
included in online supplementary appendix 2.
refining data extraction
Initially, CC extracted data on a random 10% sample 
of papers. However, some of the items were difficult to 
extract in a clear, standardised way, as similarly noted 
by Ivers et al,11 so these items were removed. In partic-
ular, whether the objectives, intervention or allocation 
concealment were at the individual level, cluster level or 
both; and other analyses performed or other unintended 
consequences (difficult to decipher from papers whether 
it classified as an ‘other’). Furthermore, some items 
were deemed easier to extract if split into two items, for 
example, ‘reported why the pilot trial ended/stopped’ 
which we subsequently split into ‘reported the pilot trial 
ended/stopped’ and ‘if so, what was the reason’.
Analysis
Data were analysed using Excel V.2013. We describe the 
characteristics of the pilot CRTs using descriptive statistics. 
Where we extracted text, we established categories during 
analysis by grouping similar data, for example, grouping 
the different primary objectives. To assess adherence to 
the CONSORT checklists, we present the number and 
percentage reporting each item. This report adheres, 
where appropriate, to the Preferred Reporting Items for 
Systematic reviews and Meta-Analyses statement.15
Patient involvement
No patients were involved in the development of the 
research question, design or conduct of the study, inter-
pretation or reporting. No patients were recruited for this 
study. There are no plans to disseminate results of the 
research to study participants.
results
The electronic PubMed search identified 257 published 
papers. We rejected 108 during screening (29 not 
reporting results; 32 not about a single randomised 
trial; 46 not cluster randomised; 1 interim analysis). The 
remaining 149 full-text articles were assessed for eligi-
bility, and 131 more papers were rejected (1 not reporting 
results; 13 not about a single randomised trial; 25 not 
cluster randomised; 8 analyses before study complete/
internal pilot; 32 not assessing feasibility; 50 not in prepa-
ration for a future definitive effectiveness/efficacy trial; 2 
not the first published paper reporting pilot outcomes). 
This left 18 studies to be included in the analysis.[A1-A18]. 
The full list of studies is included in table 1, with citations 
in online  Supplementary file 2. Figure 1 shows the flow 
diagram of the identification process for the sample of 18 
pilot CRTs.
There was 96% agreement between CC and CL for the 
10% random sample used for the screening and sifting 
validation (based on 26 papers), with a kappa coefficient 
of 0.84.
trial characteristics
In general, the more recent the publication date, the 
more pilot CRTs were identified, but with the most iden-
tified in 2013 (table 2). Of the 18 included studies, the 
majority (56%) were set in the UK. All other countries 
were represented only once except for Canada (three 
trials) and the USA (two trials). Of those reporting the 
method of randomisation, the majority (69%) used strati-
fied with blocked randomisation. The median number of 
clusters randomised was 8 (IQR: 4–16) with a range from 
2 to 50.
Pilot trial objectives and methods
Ten (56%) of the 18 included pilot trials had feasibility as 
their primary objective, for example, assessing feasibility 
of implementing the intervention (6 trials), of recruit-
ment and retention (3 trials) and of the cluster design 
(1 trial) (table 3). All 10 trials reported a corresponding 
measure to assess the feasibility objective; most (90%) 
used descriptive statistics and/or qualitative methods to 
address the objective. In one trial, a statistical test was 
used to address their primary feasibility objective without 
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Table 1 Pilot cluster randomised trials included in this review
Author Year* Journal Title Cluster
Begh
[A1]
2011 Trials Promoting smoking cessation in Pakistani 
and Bangladeshi men in the UK: pilot 
cluster randomised controlled trial of 
trained community outreach workers.
Census lower layer 
super output areas
Jones
[A2]
2011 Paediatric exercise science Promoting fundamental movement skill 
development and physical activity in early 
childhood settings: a cluster randomised 
controlled trial.
Childcare centres
Légaré
[A3]
2010 Health expectations Training family physicians in shared 
decision making for the use of antibiotics 
for acute respiratory infections: a pilot 
clustered randomised controlled trial.
Family medicine 
groups
Hopkins
[A4]
2012 Health education research Implementing organisational physical 
activity and healthy eating strategies 
on paid time: process evaluation of the 
UCLA WORKING pilot study.
Worksites—health 
and human service 
organisations
Jago
[A5]
2012 International Journal of 
Behavioral Nutrition and 
Physical Activity
Bristol girls dance project feasibility trial: 
outcome and process evaluation results.
Secondary schools
Taylor
[A6]
2011 Clinical rehabilitation A pilot cluster randomised controlled 
trial of structured goal-setting following 
stroke.
Rehabilitation services
Drahota
[A7]
2013 Age and ageing Pilot cluster randomised controlled trial 
of flooring to reduce injuries from falls in 
wards for older people.
Study areas—bays 
within hospitals
Frenn
[A8]
2013 Journal for Specialists in 
Pediatric Nursing
Authoritative feeding behaviours 
to reduce child BMI through online 
interventions.
Classrooms
Gifford
[A9]
2012 World views on evidence-
based nursing
Developing leadership capacity for 
guideline use: a pilot cluster randomised 
control trial.
Service delivery 
centres with nursing 
care for diabetic foot 
ulcers
Jones
[A10]
2013 Journal of Medical Internet 
Research
Recruitment to online therapies for 
depression: pilot cluster randomised 
controlled trial.
Postcode areas
Moore
[A11]
2013 Substance abuse treatment, 
prevention, and policy
An exploratory cluster randomised trial 
of a university halls of residence-based 
social norms marketing campaign to 
reduce alcohol consumption among first 
year students.
Residence halls
Pai
[A12]
2013 Implementation science Strategies to enhance venous 
thromboprophylaxis in hospitalised 
medical patients (SENTRY): a pilot cluster 
randomised trial.
Hospitals
Reeves
[A13]
2013 BMC health services research Facilitated patient experience feedback 
can improve nursing care: a pilot study 
for a phase III cluster randomised 
controlled trial.
Wards
Teut
[A14]
2013 Clinical interventions in 
Ageing
Effects and feasibility of an Integrative 
Medicine programme for geriatric 
patients: a cluster randomised pilot study.
Shared apartments
Jago
[A15]
2014 International journal of 
Behavioural nutrition and 
physical activity
Randomised feasibility trial of a teaching 
assistant-led extracurricular physical 
activity intervention for those aged 
9–11 years: action 3:30.
Primary schools
Continued
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Author Year* Journal Title Cluster
Michie
[A16]
2014 Contraception Pharmacy-based interventions for 
initiating effective contraception following 
the use of emergency contraception: a 
pilot study.
Pharmacies
Mytton
[A17]
2014 Health technology 
assessment
The feasibility of using a parenting 
programme for the prevention of 
unintentional home injuries in the under-
fives: a cluster randomised controlled 
trial.
Children's centres
Thomas
[A18]
2014 Trials Identifying continence options after 
stroke (ICONS): a cluster randomised 
controlled feasibility trial.
Stroke services
*We extracted the earlier of the print and electronic publication year.
Table 1 Continued 
the authors designing the study to be adequately powered 
to do so.
The remaining eight trials had an effectiveness/efficacy 
primary objective, and used statistical tests to address this. 
Nevertheless, these eight trials all had feasibility as one 
of their other objectives (this was an inclusion criterion). 
The feasibility objectives were similar to those where the 
feasibility was primary, but expressed more generally in 
two trials, for example, looking at the feasibility of the 
future definitive trial,[A16] and looking at whether the 
future definitive trial could answer the effectiveness ques-
tion and which study design would enable this.[A10] In 
only three trials was a measure to assess the feasibility 
objective reported, using either quantitative or qualitative 
measures.
Eight trials reported a rationale for the numbers in the 
pilot trial, with all of these following best practice in not 
basing the rationale on a formal sample size calculation 
for effectiveness/efficacy. Nine (50%) trials performed 
any formal hypothesis testing for effectiveness/effi-
cacy, regardless of whether this was for the primary or 
a secondary objective. Of these nine trials, four of the 
conclusions about effectiveness/efficacy were made 
without any caveats about the imprecision of estimates or 
possible lack of representativeness because of the small 
samples.
Quality of reporting—by items
The pilot CRTs in our review are published after the 
CONSORT 2010 for RCTs but before the CONSORT 
extension for pilot trials. Therefore, to present data 
on quality of reporting, we looked at our list of quality 
assessment items based on the CONSORT extension for 
pilot trials, and grouped reporting items into three cate-
gories (table 4): (1) items in the CONSORT extension 
for pilot trials that are new compared with CONSORT 
2010 for RCTs, (2) items in the CONSORT extension for 
pilot trials that are substantially adapted from CONSORT 
2010 for RCTs and (3) items in the CONSORT extension 
for pilot trials that are the same as or have only minor 
differences from CONSORT 2010 for RCTs, plus items in 
the CONSORT extension for CRTs.3 4 7 12
In the tables, denominators for proportions are based 
on papers for which the item is relevant. Not all items 
are relevant for all trials, due to their design, so we high-
light where this applies in the table footnotes. The foot-
note of table 4 also explains where the quality assessment 
items come from, with different font differentiating items 
based on the CONSORT extension for pilot trials and the 
CONSORT extension for CRTs, and a key to highlight 
which of the three categories above the item falls under.
New items
Five new items were added to the CONSORT extension 
for pilot trials on the identification and consent process, 
progression criteria, other unintended consequences, 
implications for progression and ethical approval.3 4 See 
items with [N] in column 2 of table 4. In our review, 
how participants were identified and consented was 
reported by 50% and 76% of the pilot CRTs, respectively, 
but how clusters were identified and consented was 
reported by just 33% and 11%, respectively. Only three 
trials (17%) reported criteria used to judge whether or 
how to proceed with the future definitive trial, with two 
giving numbers that must be exceeded such as recruit-
ment, retention, attendance and data collection percent-
ages,[A17, A2] and one giving categories of ‘definitely 
feasible’, ‘possibly feasible’ and ‘not feasible’.[A12] The 
item on other unintended consequences was reported by 
none of the pilot CRTs, although it is unclear whether 
this is due to poor reporting or because no unintended 
consequences occurred. Implications for progression 
from pilot to future definitive trial was reported by 16 
trials (89%), with 9 reporting to proceed/proceed with 
changes, 5 reporting further research or piloting is 
needed first and 2 reporting to not go ahead with the 
future definitive trial. Ninety-four per cent reported 
ethical approval/research review committee approval, 
but only 47% of them also reported the corresponding 
reference number.
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Figure 1 Flow diagram of the identification process for the sample of 18 pilot cluster randomised trials included in this review.
Substantially adapted items
Six items in the CONSORT extension for pilot trials were 
substantially adapted from CONSORT 2010 for RCTs, 
regarding reasons for the randomised pilot trial, sample 
size rationale for the pilot trial, numbers approached 
and/or assessed for eligibility, remaining uncertainty 
about feasibility, generalisability of pilot trial methods 
and findings and where the pilot trial protocol can be 
accessed.3 4 See items with [S] in column 2 of table 4. 
Reasons for the randomised pilot trial were reported by 
39% of the pilot CRTs. Eight trials (44%) gave a rationale 
for the sample size of the pilot trial. Pilot trials should 
always report a rationale for their sample size; this can be 
qualitative or quantitative, but should not be based on a 
formal sample size calculation for effectiveness/efficacy. 
In this review, the rationales were based on logistics,[A15] 
resources,[A14] time,[A16] a balance of practicalities and 
need for reasonable precision,[A18] a general statement 
that it was considered sufficient to address the objectives 
of the pilot trial,[A17] formal [A6] and non-formal [A7] 
calculation to enable estimation of parameters in the 
future definitive trial, and a formal calculation based 
on the primary feasibility outcome.[A12] Of these ratio-
nales, good examples include ‘The decision to include 
eight apartment-sharing communities was based on 
practical feasibility that seemed appropriate according 
to funding and the personal resources available’,[A14] 
as well as ‘The sample size was chosen in order to have 
two clusters per randomised treatment and the number 
of participants per cluster was based on the number of 
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Table 2 Characteristics of pilot cluster randomised trials 
included in this review
Characteristic Number of trials (%)
Publication year (earlier of the print and electronic 
publication date)
  2010* 1 (6)
  2011 3 (17)
  2012 3 (17)
  2013 7 (39)
  2014 4 (22)
Country
  UK 10 (56)
  Canada 3 (17)
  USA 2 (11)
  Germany 1 (6)
  New Zealand 1 (6)
  Australia 1 (6)
Method of cluster randomisation†
  Simple 1 (8)
  Stratified with blocks 9 (69)
  Blocked only 2 (15)
  Bias coin method 1 (8)
Number of clusters randomised‡
  Median (IQR) 8 (4 to 16)
  Range 2  to 50
Average cluster size§
  Median (IQR) 32 (14 to 82)
  Range 7 to 588
*One paper has an extracted publication year outside of the 
2011–2014 range. This is because the print publication date for 
this paper was 2011 but the online publication date was 2010, 
so the paper satisfies the inclusion criteria which states that the 
publication date, print or electronic, must be between 2011 and 
2014, but we extract the earlier of the print and electronic dates.
†13 of the 18 trials reported their method of randomisation. 
Percentages are given as a percentage of these 13 trials.
‡Not reported for one trial.
§Defined as number of individuals randomised divided by 
number of clusters randomised, based on 12 trials that reported 
information on both.
Table 3 Pilot trial objectives and methods
Characteristic
Number of 
trials (%)
Primary objective is feasibility* 10 (56)
Main feasibility objective given
  Where feasibility is primary objective
   Implementing intervention 6/10 (60)
   Recruitment and retention 3/10 (30)
   Feasibility of cluster design 1/10 (10)
  Where feasibility is not primary objective†
   Implementing intervention 3/8 (38)
   Recruitment 2/8 (25)
   Cluster design 1/8 (13)
   Feasibility of trial being able to answer the 
effectiveness question (and what study 
design would enable this)
1/8 (13)
   Feasibility of larger study 1/8 (13)
Method used to address main feasibility objective given
Where feasibility is primary objective
   Descriptive statistics and/or qualitative 9/10 (90)
   Statistical test 1/10 (10)
  Where feasibility is not primary objective
   Descriptive statistics/qualitative 3/8 (38)
   None given/reported elsewhere 5/8 (63)
Rationale for numbers in pilot trial based on 
formal power calculation for effectiveness/
efficacy‡
0/8 (0)
Performing any formal hypothesis testing for 
effectiveness/efficacy
9/18 (50)
Making any statements about effectiveness/
efficacy without a caveat
4/18 (22)
*Where the primary objective was not feasibility, the primary 
objective was effectiveness/potential effectiveness and was 
addressed using statistical tests.
†One of the inclusion criteria was that studies were assessing 
feasibility, but it did not have to be the primary objective.
‡Based on eight trials that reported a rationale for the sample size 
of the pilot trial.
degrees of freedom (df) needed within each cluster to 
have reasonable precision to estimate a variance’.[A6] 
The number of individuals approached and/or assessed 
for eligibility was reported by 47%, and the number of 
clusters by 56%. Remaining uncertainty was reported by 
56% of the pilot CRTs. 89% reported generalisability of 
pilot trial methods/findings to the future definitive trial 
or other studies, but clarity of reporting was lacking as 
it was difficult to distinguish between references to the 
future definitive trial versus other future studies due to 
ambiguous phrases such as ‘in a future trial’. Only 39% 
reported where the pilot trial protocol could be accessed.
Items essentially taken from CONSORT 2010 for RCTs or the 
CONSORT extension for CRTs
For the remaining items, reporting quality was variable. 
Some were reported by fewer than 20% of the pilot CRTs, 
for example, considering the cluster design in the sample 
size rationale for the pilot trial (17%) (item 7a), reporting 
whether consent was sought from clusters (11%) and who 
enrolled them (17%) (items 10 c and 10a), how people 
were blinded (7% of applicable trials) (item 11a), number 
of excluded individuals (6% of applicable trials) and clus-
ters (18% of applicable trials) after randomisation (item 
13b) and a table showing baseline cluster characteristics 
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Table 5 Number (%) of quality assessment criteria reported by each pilot cluster randomised trial in this review
Study Overall n (%)*
Title and abstract and 
introduction n (%) Methods n (%) Results n (%)
Discussion and 
other information 
n (%)
Drahota
[A7]
50 (70) 6 (86) 17 (59) 18 (78) 9 (75)
Pai
[A12]
48 (69) 5 (71) 17 (61) 18 (78) 8 (67)
Mytton
[A17]
50 (68) 4 (57) 21 (66) 13 (57) 12 (100)
Thomas
[A18]
46(67) 5 (71) 17 (59) 15 (65) 9 (90)
Teut
[A14]
49 (66) 6 (86) 20 (63) 14 (61) 9 (75)
Taylor
[A6]
47 (64) 7 (100) 16 (52) 13 (57) 11 (92)
Légaré
[A3]
42 (58) 3 (43) 18 (56) 14 (61) 7 (64)
Begh
[A1]
41 (56) 5 (71) 16 (52) 11 (48) 9 (75)
Jago
[A15]
39 (55) 4 (57) 11 (38) 13 (57) 11 (92)
Jones
[A10]
32 (52) 7 (100) 10 (33) 6 (50) 9 (75)
Moore
[A11]
37 (52) 5 (71) 13 (45) 8 (35) 11 (92)
Michie
[A16]
36 (51) 3 (43) 15 (52) 8 (36) 10 (83)
Jones
[A2]
37 (51) 3 (43) 15 (48) 10 (45) 9 (75)
Jago
[A5]
33 (46) 4 (57) 13 (45) 10 (43) 6 (50)
Gifford
[A9]
33 (45) 6 (86) 12 (39) 8 (35) 7 (58)
Reeves
[A13]
29 (41) 6 (86) 11 (38) 7 (32) 5 (42)
Frenn
[A8]
18 (26) 1 (14) 5 (17) 7 (32) 5 (42)
Hopkins
[A4]
16 (23) 2 (29) 4 (14) 4 (18) 6 (50)
*This is the overall number (percentage) of the quality assessment items in table 4 that are reported by each study. The other columns look at 
this within categories. Note that the denominator varies between studies because not all quality assessment items are relevant for all studies 
(see footnote of table 4) and not applicable for some items if a related item is not reported (see items 3b, 6b, 15, 26 in table 4).
explanation of rationale for future definitive trial (100%) 
(item 2a), pilot trial design (100%) (item 3a), nature 
of the cluster (100%) (item 3a), settings and locations 
where the data were collected (100%) (item 4b), whether 
consent was sought from participants (94%) (item 10c), 
number of clusters randomised (94%) and assessed for 
primary objective (82% of applicable trials) (item 13a), 
number of individuals assessed for primary objective 
(94% of applicable trials) (item 13a), limitations of pilot 
trial (94%) (item 20) and source of funding (100%) 
(item 25).
Quality of reporting—by study
Finally, in table 5 we present the number (percentage) 
of quality assessment items reported by each study. We 
provide an overall score, as well as a score by categories 
of CONSORT. The quality of reporting varies across 
studies, with five of the pilot CRTs reporting over 65% 
of the quality assessment items and two of the pilot CRTs 
reporting under 30%. There does not appear to be a 
trend of reporting quality with time. Five of the studies 
report 90% or more of the quality assessment items in the 
‘discussion and other information’ category, and only two 
group.bmj.com on January 13, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
12 Chan CL, et al. BMJ Open 2017;7:e016970. doi:10.1136/bmjopen-2017-016970
Open Access 
studies report <50%. Two of the studies report 100% of the 
items in the ‘title and abstract and introduction’ category, 
and five studies report <50%. The highest percentage of 
items reported by a study in the ‘methods’ category is 66% 
and the lowest is 14%. Similarly, the highest percentage 
of items reported by a study in the ‘results’ category is 
78% and the lowest is 18%. Within studies, the category 
that is best reported tends to be the ‘discussion and other 
information’ category (had the highest percentage for 10 
of the 18 pilot CRTs).
dIscussIOn
Main findings
This is the first study to assess the reporting quality of 
pilot CRTs using the recently developed CONSORT 
checklist for pilot trials.3 4 Our search strategy and inclu-
sion criteria identified 18 pilot CRTs published between 
2011 and 2014. Most studies were published in the UK, 
perhaps driven by the availability of funding or the large 
number of CRTs and interest in complex interventions in 
the UK.
With respect to the pilot CRT objectives and methods, a 
considerable proportion of papers did not have feasibility 
as their primary objective. Of the trials reporting a sample 
size rationale for the pilot, all followed best practice in 
not carrying out a formal sample size calculation for effec-
tiveness/efficacy, yet a substantial proportion performed 
formal hypothesis testing for effectiveness/efficacy. This 
could indicate an inappropriate attachment to hypothesis 
testing, although many did explain it was an indication of 
potential effectiveness or that the study was underpowered. 
Investigators wanting to assess effectiveness/efficacy and 
use statistical tests to do so should be performing a prop-
erly powered definitive trial, otherwise there is the poten-
tial for misleading conclusions affecting clinical decisions 
as well as misinformed decisions about the future defini-
tive trial.16 One may however look at potential effectiveness, 
for example, using an interim or surrogate outcome, with 
a caveat about the lack of power.3 4 Moreover, one may 
include a progression criterion based on potential effect. 
If so, Eldridge and Kerry recommend any interpretation 
of potential effect is done by looking at the limits of the 
CI,13 and one should also pay attention to features of the 
pilot which might have biased the result (eg, convenience 
sampling of clusters). A positive effect finding excluding 
the null value would still justify the future definitive trial 
to estimate the effect with greater certainty, but a nega-
tive effect finding excluding the null value (ie, strongly 
suggesting harm), or even a finding where the clinically 
important difference is excluded, might suggest not 
proceeding. It is good practice to prestate such progres-
sion criteria. Finally, one may use estimates from outcome 
data, for example, as inputs for the sample size calcula-
tion for the future definitive trial. In particular, for pilot 
CRTs we may be interested in estimating the intracluster 
correlation coefficient (ICC), although we note that the 
ICC estimate from a pilot CRT should not be the only 
source for the future definitive trial sample size, because 
of the large amount of imprecision in a pilot trial.17
Reporting quality of pilot CRTs was variable. Items 
reported well included reporting the term ‘pilot’ or ‘feasi-
bility’ in the title, generalisability of pilot trial methods/
findings to the future definitive trial or other studies 
and implications for progression from the pilot to the 
future definitive trial, although clarity could be improved 
when referring to the future definitive trial rather than 
other future studies in general. Items least well reported 
included reasons for the randomised pilot trial, sample 
size rationale for the pilot trial, criteria used to judge 
whether or how to proceed with the future definitive 
trial and where the pilot trial protocol can be accessed. 
These items are important so that readers can understand 
whether the uncertainty they are facing about their future 
trial has already been addressed in a pilot, researchers 
can make sure they have enough patients to achieve the 
pilot trial objectives, readers can understand the criteria 
for progression and to prevent against selective reporting.
For items related to the cluster aspect of pilot CRTs, 
most pilot CRTs reported the nature of the cluster, and 
the number of clusters randomised and assessed for the 
primary objective. The items reported least well included 
considering the cluster design during the sample size 
rationale for the pilot trial, reporting who enrolled clus-
ters and how they were consented, number of exclusions 
for clusters after randomisation and a table showing 
baseline cluster characteristics. Although the number of 
clusters in a pilot trial is usually small, it is still important 
to, for example, describe the cluster-level characteristics 
using a baseline table as it may give helpful information 
important for planning the future definitive trial. More-
over, while nearly all trial reports described whether 
consent was sought from individuals or not, seeking 
agreement from clusters was only described in a small 
minority. The items on agreement from and enrolment 
of clusters, baseline cluster characteristics and number 
of excluded clusters are particularly important to report, 
since they may affect assessment of feasibility.
If we consider why some items may have been well 
adhered to and others not, it is interesting to observe that 
new items added to the CONSORT extension for pilot 
trials and items substantially adapted from CONSORT 
2010 for RCTs were in general not well adhered to. This 
could perhaps be because of somewhat newer ideas that 
may not have been considered during design such as spec-
ifying progression criteria and considering a rationale for 
numbers in the pilot. Alternatively, perhaps there were 
aspects sometimes done but not reported due to lack of 
reporting guidance to remind authors; for example, the 
new items on how clusters were identified and consented, 
other unintended consequences and ethical approval/
research review committee approval reference number, 
and the substantially adapted items on reporting reasons 
for the pilot trial, number of individuals approached 
and/or assessed for eligibility and where the pilot trial 
protocol can be accessed. With the item on unintended 
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consequences, we recognise that investigators are free 
to choose what they interpret and report as an unin-
tended consequence. We recommend careful thought 
that all unintended consequences that may affect the 
future definitive trial are reported. It is also interesting 
to observe that many of the most poorly reported items 
concerned methods/design (progression criteria; enrol-
ment and consent of clusters), and in particular, justifica-
tion of design aspects (reasons for randomised pilot trial; 
sample size rationale for pilot trial including consider-
ation of cluster design). Within studies, the category that 
is worst reported is the methods, despite being crucial to 
allow the reader to judge the quality of the trial.
comparison with other studies
There has not been a previous review of pilot trials using 
the new CONSORT extension for pilot trials.3 4 However, 
the review by Arain et al looking at pilot and feasibility 
studies reported that 81% were performing hypothesis 
testing with sample sizes known to be insufficient,6com-
pared with 50% of pilot CRTs in our review. Arain et al 
also reported 36% of studies performing sample size 
calculations for the pilot. In our review, 17% performed 
calculations (all based on feasibility objectives), but if we 
include those that also correctly reported a rationale for 
the numbers in the pilot but without any calculation then 
this was 44%.
The general message that reporting of CRTs is subop-
timal still holds.8–11 The review by Diaz-Ordaz et al8 of 
definitive trial CRTs reported that 37% presented a table 
showing baseline cluster characteristics, compared with 
11% of pilot CRTs in our review. Diaz-Ordaz et al8 also 
reported that 27% accounted for clustering in sample size 
calculations,8 and a recent review by Fiero et al reported 
53%.10 However, just 17% of pilot CRTs in our review 
considered the cluster design in the sample size rationale 
for the pilot trial. Both these CRT reviews reviewed effec-
tiveness/efficacy CRTs, for which the need to take account 
of clustering in sample sizes is generally well understood 
compared with pilot trials. In pilot trials, the rationale for 
considering the clustered design in deciding on numbers 
in the pilot may be different, for example, considering 
the number of df needed within each cluster to estimate 
a variance.[A6] In pilot trials, including a number of clus-
ters with different characteristics may also be important 
to get an idea about the implementation of an interven-
tion across different clusters.
strengths and limitations
We used a robust search and data extraction procedure, 
including validation of the screening/sifting process and 
double data extraction. However, the use of only one data-
base, PubMed, which is comprehensive but not exhaustive, 
may have missed eligible papers, and the use of conditions 
#3, #5 and #6 (see online supplementary appendix 1) may 
have been restrictive. Our aim was to get a general idea of 
reporting issues in the area, rather than doing a completely 
comprehensive search. Our inclusion criteria stipulated that 
papers must have the word ‘pilot’ or ‘feasibility’ in the title 
or abstract, so we may have missed some pilot CRTs and thus 
may have overestimated the percentage reporting ‘pilot’ or 
‘feasibility’ in the title. This strategy may also have resulted 
in a skewed sample of papers with a greater tendency to 
adhere to CONSORT guidelines. However, our review 
suggests reporting of pilot CRTs need improving, so our 
conclusion would remain the same. We required authors to 
report that the trial was in preparation for a future definitive 
trial, so we expect that items related to the future definitive 
trial (eg, progression criteria, generalisability, implications) 
may be better reported than they would for all publica-
tions of pilot CRTs, which might include papers that did 
not report that they were in preparation for a future defin-
itive trial clearly enough to be included. During sifting, we 
identified 32 trials that had ‘pilot’ or’ feasibility’ in the title/
abstract, but were not assessing feasibility. A third of these 
were identified because they referred to ‘pilot’ or ‘feasi-
bility’ at some point in the abstract but it was not in refer-
ence to the current trial (eg, stating feasibility has already 
been shown), but the other two-thirds were labelled as a 
pilot or feasibility trial yet showed no evidence of assessing 
feasibility and were only assessing effectiveness. This is an 
important point as our review may appear to overestimate 
reporting quality by not including these studies. That there 
are underpowered main trials being published as pilot or 
feasibility studies is something that the academic commu-
nity should look to prevent. During sifting, we also identi-
fied 50 trials that were assessing feasibility but did not show 
evidence of being in preparation for a future definitive trial. 
Most were assessing the feasibility of implementing an inter-
vention targeted at members of the public, or discussing 
feasibility of the intervention with the aim of providing 
information to help researchers wanting to implement a 
similar intervention in similar settings or to raise questions 
for future research, rather than being in preparation for a 
trial assessing effectiveness/efficacy. Some of these 50 trials 
also appeared to be small effectiveness studies labelled as 
a pilot, usually only mentioning feasibility once or twice 
throughout the paper, with one trial explicitly stating that 
“Because of organisational changes… we had to stop the 
inclusion after 46 participants, and the study is consequently 
defined as a pilot study”.18 For the few trials that were poten-
tially pilot CRTs not reported clearly enough, the authors 
only spoke of future studies in general rather than clearly 
specifying the study was in preparation for a specific future 
definitive trial. Related to this, it is of interest to know the 
proportion of our 18 pilot CRTs that are actually followed 
by a future definitive trial, and we plan to investigate this in 
future.
cOnclusIOn
We may have overestimated the reporting quality of 
pilot CRTs; nevertheless, our review demonstrates that 
reporting of pilot CRTs need improving. The identifica-
tion of just 18 pilot CRTs between 2011 and 2014, mainly 
from the UK, highlights the need for increased awareness 
group.bmj.com on January 13, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
14 Chan CL, et al. BMJ Open 2017;7:e016970. doi:10.1136/bmjopen-2017-016970
Open Access 
of the importance of carrying out and publishing pilot 
CRTs and good reporting so that these studies can be iden-
tified. Pilot CRTs should primarily be assessing feasibility, 
and avoiding formal hypothesis testing for effectiveness/
efficacy. Improvement is needed in reporting reasons 
for the pilot, rationale for the pilot trial sample size and 
progression criteria, as well as the enrolment stage of clus-
ters and how the cluster design affects aspects of design 
such as numbers of participants. We recommend adher-
ence to the new CONSORT extension for pilot trials, in 
conjunction with the CONSORT extension for CRTs.3 4 7 
We encourage journals to endorse the CONSORT state-
ment, including extensions.
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